Across Europe, a quiet crisis of the nervous system is exacting a measurable toll: Parkinson's disease cost the continent €22.8 billion in a single year, a sum that reflects not only the price of medicine and care, but the invisible labor of families and the productivity lost to illness. With 2.2 million Europeans living with the condition in 2019—and prevalence nearly double what it was in 1990—the disease is expanding faster than the systems designed to meet it. Researchers are now calling for standardized accounting across borders, recognizing that what cannot be measured consistently canno
Parkinson's disease costs Europe €22.8 billion annually, study finds
Approximately 2.2 million adults across Europe live with Parkinson's disease, placing substantial demands on caregivers and health systems.
Nearly doubled since 1990, and still climbing.
Mark
So we're talking about 22.8 billion euros in a single year. That's a real number—not an estimate of what *might* happen, but what *did* happen in 2019?
Mimi
Yes. That's the measured cost across 47 European countries in 2019. When you adjust it for inflation to 2025 prices, it becomes 28.8 billion.
Luke
But here's the thing—that 22.8 billion only covers 43 of those 47 countries. They had no cost data from lower-middle-income countries, so the actual European total could be higher. We just don't know.
Mark
Why the data gap?
Mimi
Most of the cost studies came from wealthy nations. Poorer countries either haven't done these studies or haven't published them in ways researchers could access.
Luke
Right. So when they say 2.2 million people have Parkinson's across Europe, that's probably accurate—that's prevalence data. But the cost figure is incomplete.
Mark
And the breakdown—76 percent direct medical costs, 19 percent unpaid care. Is that solid?
Mimi
It's based on the studies they could find. But again, if you're missing data from entire regions, you're missing pieces of the picture.
Mark
What about the five countries that account for 75 percent of costs? Is that because they have more Parkinson's, or because they spend more?
Mimi
Both. Germany, France, Italy, Spain, and the UK have large populations and aging demographics. But wealthier countries also have more expensive healthcare systems and better data collection.
Luke
So you can't really say Germany has a worse Parkinson's problem than, say, Poland. You can only say Germany's costs are documented and higher. That's different.
Il Polso
- Parkinson's disease is the world's fastest-growing neurodegenerative disorder, and Europe is feeling its acceleration—prevalence has nearly doubled since 1990, climbing from 135 to 247 cases per 100,000 people.
- The €22.8 billion annual burden falls unevenly: Germany, France, Italy, Spain, and the United Kingdom together absorb roughly three-quarters of the continent's total costs, exposing deep disparities in both disease load and care expenditure.
- Unpaid family caregiving—valued at €4.4 billion—remains largely invisible in policy discussions, yet it constitutes nearly a fifth of the total economic burden.
- A critical gap undermines the full picture: 13 of 14 cost studies came from high-income countries, leaving lower-middle-income European nations without primary data and the €22.8 billion figure covering only 43 of 47 assessed countries.
- Researchers and the European Academy of Neurology are pressing for standardized cost-measurement methods across the continent, arguing that coherent evidence is the prerequisite for any meaningful healthcare planning.
Across Europe, a quiet crisis of the nervous system is exacting a measurable toll: Parkinson's disease cost the continent €22.8 billion in a single year, a sum that reflects not only the price of medicine and care, but the invisible labor of families and the productivity lost to illness. With 2.2 million Europeans living with the condition in 2019—and prevalence nearly double what it was in 1990—the disease is expanding faster than the systems designed to meet it. Researchers are now calling for standardized accounting across borders, recognizing that what cannot be measured consistently cannot be planned for wisely.
In 2019, Parkinson's disease cost Europe €22.8 billion—a figure that rises to €28.8 billion in 2025 values. Published in Movement Disorders and drawn from the Cost of Illness in Neurology in Europe initiative, the study mapped the disease's economic weight across 47 countries, finding that roughly 2.2 million adults were living with the condition that year.
The costs divide into three streams. Direct medical and non-medical expenses—hospital care, medications, social services, home adaptations—consumed €17.3 billion, or about three-quarters of the total. Unpaid care provided by family and friends added €4.4 billion, while lost productivity accounted for another €1 billion. The burden was heavily concentrated: Germany, France, Italy, Spain, and the United Kingdom together bore roughly three-quarters of Europe's entire Parkinson's bill.
The urgency behind these numbers lies in the disease's trajectory. Parkinson's is both the second most common neurodegenerative disorder and the fastest-growing, with European prevalence nearly doubling since 1990. Aging populations, better diagnostic tools, and sharper clinical recognition are all accelerating that trend, placing mounting pressure on health and social care systems.
The study also revealed significant gaps. Nearly all cost data came from high-income countries, leaving lower-middle-income European nations unrepresented and the €22.8 billion figure incomplete. The authors call for standardized cost-measurement methods across the continent—a prerequisite, they argue, for consistent evidence and sound planning. For policymakers, the findings offer both a foundation and a warning: the weight of Parkinson's is growing, and Europe's fragmented health systems must decide how to meet it.
Across Europe, Parkinson's disease carried a price tag of €22.8 billion in 2019—a figure that balloons to €28.8 billion when adjusted to 2025 currency values. That is the finding of a study published in Movement Disorders, one that arrives as the disease's footprint on the continent continues to expand.
About 2.2 million adults were living with Parkinson's across 47 European countries in that year. The disease's economic weight breaks down into three categories: direct medical and non-medical expenses—hospital stays, drugs, social services, home modifications—consumed €17.3 billion, or roughly three-quarters of the total. Unpaid care from family members and friends accounted for €4.4 billion. Lost productivity from illness cost another €1 billion. The burden is not evenly distributed. Germany bore the heaviest load at €5.7 billion annually, trailed by France at €5.3 billion, Italy at €2.6 billion, Spain at €1.9 billion, and the United Kingdom at €1.6 billion. These five nations alone absorbed about three-quarters of Europe's entire Parkinson's bill.
What makes this accounting urgent is the trajectory of the disease itself. Parkinson's is the world's second most common neurodegenerative disorder and the fastest-growing. Since 1990, its prevalence across Europe has nearly doubled, climbing from 135 cases per 100,000 people to 247. The drivers are familiar: populations aging, diagnostic tools improving, disease recognition sharpening. As these trends persist, health and social care systems face mounting strain.
The research emerged from the Cost of Illness in Neurology in Europe initiative, led by the European Academy of Neurology. Researchers merged prevalence data from the Global Burden of Disease Study with cost figures drawn from a systematic review of published European studies. The approach allowed them to model expenses for each country based on available evidence. Richard Dodel, a professor at the University Duisburg-Essen, noted that the concentration of costs in wealthier nations reflects not just population size and disease prevalence, but also the quality and expense of care systems themselves—wealthier countries spend more per patient, and they have better data.
Yet the study also exposed significant blind spots. Of 14 eligible cost studies in the analysis, 13 came from high-income countries. No primary cost data existed from lower-middle-income European nations, meaning the €22.8 billion figure actually covers only 43 of the 47 countries assessed for disease prevalence. The authors call for standardized methods of measuring Parkinson's costs across the continent, a step they argue is essential for consistent evidence and sound healthcare planning.
Günther Deuschl, founding president of the European Academy of Neurology, framed the findings as a foundation for policymakers and healthcare planners to grasp the growing weight of Parkinson's and prepare for future demand. The academy, he said, will continue tracking the burden and costs of neurological diseases as part of its broader mission to improve life for people living with these conditions. The question now is whether Europe's fragmented health systems can absorb the answer.
Citazioni salienti
The concentration of costs in these five countries is likely due to a combination of their large populations, higher age-related prevalence of Parkinson's disease, higher healthcare costs in wealthier countries and the greater availability of data.— Professor Richard Dodel, University Duisburg-Essen
These findings provide policymakers, healthcare planners and the neurological community with important evidence to better understand the growing burden of Parkinson's disease and to plan for future care needs.— Professor Günther Deuschl, European Academy of Neurology
Vuoi la storia completa?
Leggi l'originale su News-Medical ↗
Science & Space